Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine

Next Previous
Trial Profile

A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 1222 (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate; Paracetamol
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms COV003

Most Recent Events

  • 19 Jan 2022 Planned End Date changed to 31 Mar 2023.
  • 03 Jan 2022 Status changed from active, no longer recruiting to completed.
  • 21 May 2021 According to an AstraZeneca media release, based on data from this trial and Phase III efficacy and safety data from the Oxford University-led clinical trial programme in the UK and South Africa and a Phase I/II trial in Japan the Japanese Ministry of Health, Labour and Welfare granted a special approval to Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222 for emergency use in Japan for active immunisation of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top